Sign In
PROG.US
id: 1282

Progenity (PROG) Investor Settlement

The settlement terms have been submitted to the court for approval.
$1,000,000
Cash Settlement
S.D. California
Court
3:20-cv-01683
Case number
06/22/2020
Class period Start
08/28/2020
Class period End
Progenity ($PROG) has agreed to settle $1 million with investors to resolve claims that it misled them about overbilling issues and financial risks ahead of its IPO.


Outline


In 2020, Progenity was accused of overstating revenues and failing to disclose a $49 million government settlement tied to overbilling. By August, the company reported weak financials and $PROG dropped 50%. Following this, Progenity faced a lawsuit from investors.

Timeline

  • June 22, 2020 – Progenity held its IPO, selling 6.6 million shares and generating over $100 million in gross proceeds.
  • July–August 2020 – Progenity announced a $49 million proposed settlement to resolve government investigations into overbilling. As part of this, it set aside $10.3 million to refund government health programs for overbilling.
  • August 14, 2020 – Following this news, $PROG declined nearly 50%.
  • October 27, 2020 – Investors filed a lawsuit, alleging Progenity misled them about financial risks and overbilling issues.
  • September 19, 2024 – Progenity finalized a $1 million settlement with investors.

Background

Progenity launched its IPO in June 2020, raising over $100 million. At the time, the company claimed it was well-positioned for growth through its core genetic testing business.

However, at that point, Progenity had already agreed in principle to a $49 million settlement with the government over improper billing and illegal marketing practices.

Specifically, the company had billed government healthcare programs using incorrect codes and waived patient copays to boost test volumes—actions that violated federal laws.

Progenity continued these practices until February 2020, when it abruptly ended its discount program amid mounting regulatory pressure.
Internally, the company had also identified that it had likely received substantial overpayments for its Preparent tests and later confirmed a $10.3 million charge for expected refunds.

By August 2020, Progenity reported weak revenues and test volumes, revealing a declining trend that had started before the IPO but was not disclosed to investors.

Following this news, $PROG plummeted nearly 50%.

On October 27, 2020, investors filed a lawsuit against Progenity.


What Can Investors Expect Now?


Progenity ($PROG) has agreed to settle $49 million with investors to resolve claims that it misled them about overbilling issues and financial risks ahead of its IPO.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section below.
Case Type
US Securities Class Action
Case Status
Stipulative Settlement
Alleged Offence
Mismanagement
Misleading Statements
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.21
Filing date
10/27/2020
Plaintiffs
Lin Shen
Defendants
Harry Stylli, Eric d’Esparbes, Jeffrey Alter, John Bigalke, Jeffrey Ferrell, Brian L. Kotzin, Samuel Nussbaum, Lynne Powell
Judge
William Q. Hayes
Administrator
Strategic Claims Services
Settlement agreement date
2024-09-19
Attorney fee
$435,833
Trades matching type
FIFO

Frequently Asked Questions

Progenity Inc

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, inclu...

    Ticker
    PROG.US
    ISIN
    US74319F1075
    CIK
    0001580063
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    4330 La Jolla Village Drive, San Diego, CA, United States, 92122